CULIV is a pharmaceutical injection composed of L-Ornithine L-Aspartate (LOLA), which is typically used in the management of conditions related to liver function. This formulation is particularly effective in treating hepatic encephalopathy, a decline in brain function due to severe liver disease. L-Ornithine and L-Aspartate work synergistically to help detoxify ammonia, a byproduct of protein metabolism that can accumulate to toxic levels in individuals with liver impairment.

The key mechanisms by which CULIV works include enhancing the urea cycle function, which helps in converting ammonia into urea, and subsequently facilitating its excretion from the body. Additionally, L-Ornithine L-Aspartate can also stimulate the synthesis of glutamine in the muscles and brain, further aiding in the reduction of ammonia levels.



CULIV, an intravenous pharmaceutical injection, contains the active ingredients L-Ornithine and L-Aspartate, which are essential in the management of liver-related conditions, particularly hepatic encephalopathy. This medical formulation plays a crucial role in enhancing liver function by aiding in the detoxification process. It specifically targets the reduction of elevated ammonia levels in the blood, a common issue in patients with compromised liver health. By supporting the urea cycle and promoting the synthesis of beneficial compounds like glutamine, CULIV helps mitigate the neurological symptoms associated with liver dysfunction, offering a therapeutic advantage in critical care settings.

This medication is typically administered intravenously and is used in hospital settings under strict medical supervision. It is crucial for patients receiving this treatment to be closely monitored for efficacy and potential side effects. Common uses include acute and chronic hepatic encephalopathy and it may be part of supportive therapy for patients with severe liver disease awaiting liver transplantation or recovering post-transplant.


The CULIV injection, containing L-Ornithine L-Aspartate, offers several benefits for patients with liver disorders, especially those suffering from hepatic encephalopathy. Here are some of the key advantages of using this medication:

  1. Ammonia Detoxification: CULIV helps reduce high levels of ammonia in the blood, which is crucial for patients with liver impairment. Ammonia is a toxic byproduct that can accumulate when the liver is unable to process it adequately. By assisting in ammonia detoxification, the injection can help alleviate symptoms related to hepatic encephalopathy.

  2. Enhancement of Liver Function: The components of CULIV support the urea cycle, a critical pathway in the liver that converts toxic ammonia into urea, which is then eliminated from the body through urine. This enhancement of the urea cycle helps improve overall liver function.

  3. Reduction in Neurological Symptoms: By lowering ammonia levels, CULIV can reduce neurological symptoms associated with hepatic encephalopathy, such as confusion, altered level of consciousness, and coma. This is particularly important for improving the quality of life in patients with severe liver disease.

Open chat
Need Help?
How can I help you?